As of June 30, 2026, the fair values of our financial assets and liabilities were categorized as follows:


	Total		Level 1		Level 2		Level 3
Assets
Investment in equity securities (1)	$	2,215	$	2,215	$	—	$	—
Foreign exchange contracts (2)	625		—		625		—

Convertible notes (3)	5,000		—		—		5,000
Total assets at fair value	$	7,840	$	2,215	$	625	$	5,000
Liabilities
Foreign exchange contracts (2)	$	1,045	$	—	$	1,045	$	—
Cross-currency swap contract (2)	24,654		—		24,654		—
Contingent consideration obligation	253		—		—		253
Total liabilities at fair value	$	25,952	$	—	$	25,699	$	253

As of December 31, 2025, the fair values of our financial assets and liabilities were categorized as follows:


	Total		Level 1		Level 2		Level 3
Assets
Investment in equity securities (1)	$	2,503	$	2,503	$	—	$	—
Foreign exchange contracts (2)	298		—		298		—

Convertible notes (3)	5,650		—		—		5,650
Total assets at fair value	$	8,451	$	2,503	$	298	$	5,650
Liabilities
Foreign exchange contracts (2)	$	632	$	—	$	632	$	—
Cross-currency swap contract (2)	32,542		—		32,542		—
Contingent consideration obligation	3,983		—		—		3,983
Total liabilities at fair value	$	37,157	$	—	$	33,174	$	3,983

(1)Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 17 – Investment in Equity Securities for discussion of this investment.

(2)Market approach valuation technique based on observable market transactions of spot and forward rates.

(3)Investment in convertible notes in Enable Injections, Inc. The investment is included within Miscellaneous assets in our Condensed Consolidated Balance Sheets.